Publicacións en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (19)

2024

  1. Technique and impact on first pass effect primary results of the ASSIST global registry

    Journal of NeuroInterventional Surgery

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Genome-wide analyses characterize shared heritability among cancers and identify novel cancer susceptibility regions

    Journal of the National Cancer Institute, Vol. 115, Núm. 6, pp. 712-732

  3. Left atrial appendage closure during cardiac surgery: Safe but underutilized in California

    JTCVS Open, Vol. 13, pp. 150-162

  4. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes from the Phase 3 KEYNOTE-189 Study

    Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 1992-1998

2022

  1. Center-Level Variation in Transplant Rates Following the Heart Allocation Policy Change

    JAMA Cardiology, Vol. 7, Núm. 3, pp. 277-285

  2. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

  3. Nontechnical skills training in cardiothoracic surgery: A pilot study

    Journal of Thoracic and Cardiovascular Surgery, Vol. 163, Núm. 6, pp. 2155-2162.e4

2021

  1. Impact of Payer Status on Delisting Among Liver Transplant Candidates in the United States

    Liver Transplantation, Vol. 27, Núm. 2, pp. 200-208

  2. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

    Annals of Oncology, Vol. 32, Núm. 7, pp. 881-895

2020

  1. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 3, pp. 387-397

  2. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 14, pp. 1505-1517

2019

  1. Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (Nature Genetics, (2019), 51, 3, (414-430), 10.1038/s41588-019-0358-2)

    Nature Genetics

  2. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing

    Nature Genetics, Vol. 51, Núm. 3, pp. 414-430

  3. Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)

    Nature Communications

  4. Shared heritability and functional enrichment across six solid cancers

    Nature Communications, Vol. 10, Núm. 1

2018

  1. KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?

    Annals of Oncology, Vol. 29, pp. ix164

  2. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer

    New England Journal of Medicine, Vol. 378, Núm. 22, pp. 2078-2092

2015

  1. Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium

    EBioMedicine, Vol. 2, Núm. 11, pp. 1677-1685